Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026, reflecting deteriorating fundamentals and technical indicators. The micro-cap pharmaceutical company’s financial trend has shifted from positive to flat, valuation metrics have worsened to risky territory, and technical signals have turned bearish, signalling heightened caution for investors.

Welcure Drugs & Pharmaceuticals Ltd has experienced a marked deterioration in its valuation parameters, shifting from very attractive to risky territory, as reflected in its price-to-earnings and price-to-book value ratios. This change, coupled with a significant decline in share price and underperformance relative to the Sensex, raises concerns about the stock’s price attractiveness and investment appeal within the Pharmaceuticals & Biotechnology sector.

Welcure Drugs & Pharmaceuticals Ltd. reported a catastrophic fourth quarter for FY26, posting a net loss of ₹49.86 crores compared to a profit of ₹2.54 crores in the same quarter last year. The micro-cap pharmaceutical company's shares, trading at ₹0.29 on the NSE, have plunged 73.15% over the past year, reflecting investor alarm over the dramatic deterioration in operational performance.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 14 Nov 2025, reflecting a change in the company’s outlook at that time. However, all fundamentals, returns, and financial metrics discussed below are current as of 23 April 2026, providing an up-to-date view of the stock’s position in the market.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

A steep decline has pushed Welcure Drugs & Pharmaceuticals Ltd to a fresh 52-week low of Rs 0.23 on 1 Apr 2026, marking a significant 68.82% drop over the past year despite a broader market that has been relatively resilient.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low price of Rs.0.24, marking a significant decline in its stock value amid a challenging market environment and company-specific factors.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low price of Rs.0.25, marking a significant decline in its stock value amid broader market pressures and company-specific factors.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low of Rs.0.26 today, marking a significant decline in its stock price amid a challenging market environment. This latest low reflects a year-long downward trend, with the stock underperforming its sector and benchmark indices.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low of Rs.0.27, marking a significant decline in its stock price amid broader market weakness and sectoral pressures.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Welcure Drugs & Pharmaceuticals Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive valuation grade. This change is underscored by its exceptionally low price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both its historical averages and peer group benchmarks, signalling a potential opportunity for value investors amid a challenging market backdrop.

Welcure Drugs & Pharmaceuticals Ltd has reported a mixed quarterly performance for December 2025, reflecting a shift from very positive to positive financial trends. While net sales and profit after tax (PAT) have shown robust growth over the last six months, recent quarterly margins have contracted sharply, signalling operational challenges despite top-line momentum.